Adding pembrolizumab to chemoradiotherapy improves survival in newly diagnosed locally advanced cervical cancer. Despite that, the addition of the immunotherapy was not found to be cost-effective at a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The addition of pembrolizumab to chemotherapy as ...
The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) or pembrolizumab and berahyaluronidase alfa-pmph ...
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with ...
The FDA has approved enfortumab vedotin (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) or subcutaneous pembrolizumab (Keytruda Qlex, Merck) for the neoadjuvant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results